AWARE

Novo Nordisk to present new cardiometabolic disease data, including results from SELECT, at the annual American Heart Association Scientific Sessions

Retrieved on: 
Tuesday, November 7, 2023
Science, Heart failure, Quality of life, Treatment, Comorbidity, Novo Nordisk, Diabetes, American Heart Association, Doctor of Philosophy, Research, Drug development, Risk, Partnership, Abstract, STEP, AWARE, Phenotype, SELECT, AHA, Nordisk, Pharmaceutical industry, Obesity

Results will be presented at the upcoming American Heart Association's (AHA) annual Scientific Sessions in Philadelphia, Pennsylvania from November 11-13, 2023.

Key Points: 
  • Results will be presented at the upcoming American Heart Association's (AHA) annual Scientific Sessions in Philadelphia, Pennsylvania from November 11-13, 2023.
  • Late-breaking scientific abstracts will be posted online at the exact date and time the embargo lifts.
  • Data from the SELECT trial will be presented live during a late-breaking science session at 8:30-9:15 AM EST on November 11.
  • As expected, there is significant risk with drug development and no guarantee that future studies will reflect similar results as presented at AHA.

A2 Bio Presents Oral and Poster Presentations Highlighting BASECAMP-1 and EVEREST-1 Patient Screening at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Retrieved on: 
Thursday, November 2, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, Tempus, Neoplasm, Patient, CAR, Society for Immunotherapy of Cancer, MSLN, Carcinoembryonic antigen, Cell, NYU, SITC, Immunotherapy, Lung, NGS, CEA, Medicine, AWARE, Annual general meeting, Mesothelioma, HLA, Pharmaceutical industry, Medical imaging, Vaccine, A2

Additionally, A2 Bio is presenting two posters on November 4, 2023, detailing the BASECAMP-1 master pre-screening trial and EVEREST-1 CAR T interventional trial.

Key Points: 
  • Additionally, A2 Bio is presenting two posters on November 4, 2023, detailing the BASECAMP-1 master pre-screening trial and EVEREST-1 CAR T interventional trial.
  • “BASECAMP-1 provides patients an early opportunity to be identified and triaged to the appropriate EVEREST logic-gate Tmod™ CAR T trial.
  • A2 Bio has partnered with Tempus, a leader in precision medicine, to bring the latest technology to patient screening.
  • Details of the presentations are below:
    The two posters will be available on the A2 Bio website after November 4, 2023.

Jonathan Milner Issues Statement Responding to the Glass Lewis Report

Retrieved on: 
Monday, October 23, 2023
ACT, MAKE, ITS, TAX, FOR, PAST, FAIR, DATE, AS, UPDATE, SET, ANY, NO, AMERICA, FCA, EUROPEAN UNION, BY, FUTURE, FINANCIAL, III, TIME, UPON, NOT, EACH, AND, ALL, PER, THIS, OF, EXPRESS, AWARE, IS, NORTH, USE, IT, Glass fiber, Medical device, Audit, EU

T: +44 7733 265 198 / E: [email protected]

Key Points: 
  • T: +44 7733 265 198 / E: [email protected]
    T: +44 (0)20 3709 5700 / E: [email protected]
    T: +1 646 677 1811 / E: [email protected]
    THIS DOCUMENT HAS BEEN ISSUED BY DR. JONATHAN MILNER ("DR. MILNER").
  • DR. MILNER STRONGLY ADVISES ALL SHAREHOLDERS OF THE COMPANY TO READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION.
  • THE VIEWS EXPRESSED HEREIN REPRESENT THE OPINIONS OF DR. MILNER AS OF THE DATE HEREOF.
  • DR. MILNER HAS NOT SOUGHT OR OBTAINED CONSENT FROM ANY THIRD PARTY TO USE ANY STATEMENTS OR INFORMATION CONTAINED HEREIN.

Jonathan Milner Issues Statement Responding to ISS Report

Retrieved on: 
Monday, October 16, 2023
MAKE, ACT, III, AWARE, NO, AMERICA, NOT, PAST, TIME, DATE, THIS, AS, NORTH, USE, ANY, OF, IT, FOR, UPON, FINANCIAL, FCA, ITS, SET, IS, TAX, EXPRESS, EUROPEAN UNION, ALL, FAIR, UPDATE, BY, FUTURE, EACH, AND, Glass fiber, Medical device, Audit, EU

T: +44 7733 265 198 / E: [email protected]

Key Points: 
  • T: +44 7733 265 198 / E: [email protected]
    T: +44 (0)20 3709 5700 / E: [email protected]
    T: +1 646 677 1811 / E: [email protected]
    THIS DOCUMENT HAS BEEN ISSUED BY DR. JONATHAN MILNER ("DR. MILNER").
  • DR. MILNER STRONGLY ADVISES ALL SHAREHOLDERS OF THE COMPANY TO READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION.
  • THE VIEWS EXPRESSED HEREIN REPRESENT THE OPINIONS OF DR. MILNER AS OF THE DATE HEREOF.
  • DR. MILNER HAS NOT SOUGHT OR OBTAINED CONSENT FROM ANY THIRD PARTY TO USE ANY STATEMENTS OR INFORMATION CONTAINED HEREIN.

Jonathan Milner releases presentation to Abcam plc shareholders, outlining reasons to reject Danaher's bid and strategic vision for the Company

Retrieved on: 
Monday, October 16, 2023
ACT, MAKE, III, AWARE, NO, AMERICA, NOT, PAST, TIME, DATE, THIS, AS, NORTH, USE, ANY, OF, IT, FOR, UPON, PER, FINANCIAL, FCA, ITS, SET, IS, TAX, EXPRESS, EUROPEAN UNION, ALL, FAIR, UPDATE, BY, FUTURE, EACH, AND, Glass fiber, Medical device, Audit, EU

DR. MILNER STRONGLY ADVISES ALL SHAREHOLDERS OF THE COMPANY TO READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION.

Key Points: 
  • DR. MILNER STRONGLY ADVISES ALL SHAREHOLDERS OF THE COMPANY TO READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION.
  • THE VIEWS EXPRESSED HEREIN REPRESENT THE OPINIONS OF DR. MILNER AS OF THE DATE HEREOF.
  • DR. MILNER IS NOT RESPONSIBLE TO ANY PERSON FOR PROVIDING ADVICE IN RELATION TO THE SUBJECT MATTER OF THIS DOCUMENT.
  • DR. MILNER HAS NOT SOUGHT OR OBTAINED CONSENT FROM ANY THIRD PARTY TO USE ANY STATEMENTS OR INFORMATION CONTAINED HEREIN.

Jonathan Milner issues Open Letter to shareholders of Abcam plc

Retrieved on: 
Tuesday, October 10, 2023
MAKE, ACT, III, AWARE, NO, AMERICA, NOT, PAST, TIME, DATE, THIS, AS, NORTH, USE, ANY, OF, IT, FOR, UPON, FINANCIAL, FCA, ITS, SET, IS, TAX, EXPRESS, EUROPEAN UNION, ALL, FAIR, UPDATE, BY, FUTURE, EACH, AND, Glass fiber, Medical device, Audit, EU

T: +44 7733 265 198 / E: [email protected]

Key Points: 
  • T: +44 7733 265 198 / E: [email protected]
    T: +44 (0)20 3709 5700 / E: [email protected]
    T: +1 646 677 1811 / E: [email protected]
    THIS DOCUMENT HAS BEEN ISSUED BY DR. JONATHAN MILNER ("DR. MILNER").
  • DR. MILNER STRONGLY ADVISES ALL SHAREHOLDERS OF THE COMPANY TO READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION.
  • THE VIEWS EXPRESSED HEREIN REPRESENT THE OPINIONS OF DR. MILNER AS OF THE DATE HEREOF.
  • DR. MILNER HAS NOT SOUGHT OR OBTAINED CONSENT FROM ANY THIRD PARTY TO USE ANY STATEMENTS OR INFORMATION CONTAINED HEREIN.

NINJIO gives companies free access to next-gen training resources for National Cybersecurity Awareness Month

Retrieved on: 
Monday, October 2, 2023
NCA, Friends, Face, Culture, Workplace, Fear, Cybersecurity and Infrastructure Security Agency, AWARE, CISA, National Cybersecurity Center of Excellence, Machine learning, Risk, SENSE, Knowledge, AI, Behavior, CSAT, Computer security, Medical device

LOS ANGELES, Oct. 2, 2023 /PRNewswire/ -- This year marks the 20th anniversary of National Cybersecurity Awareness Month. NINJIO, an industry-leading provider of cybersecurity awareness training (CSAT) solutions, is participating by joining the Cybersecurity and Infrastructure Security Agency (CISA) and the National Cybersecurity Alliance (NCA) to ensure that Americans have the knowledge and resources they need to stay safe online.

Key Points: 
  • NINJIO , an industry-leading provider of cybersecurity awareness training (CSAT) solutions, is participating by joining the Cybersecurity and Infrastructure Security Agency (CISA) and the National Cybersecurity Alliance (NCA) to ensure that Americans have the knowledge and resources they need to stay safe online.
  • By providing free access to our SENSE Sampler Pack during National Cybersecurity Awareness Month, we're giving companies the behavioral tools they need to navigate the ever-shifting cyberthreat landscape."
  • NINJIO AWARE and SENSE help companies develop a culture of cybersecurity awareness at every level of the organization.
  • During National Cybersecurity Awareness Month, we hope companies will give our platform a try to determine what their vulnerabilities are and how they can protect themselves from cyberattacks."

Dr. Jonathan Milner opposes Danaher's acquisition of Abcam and calls for EGM to replace Board

Retrieved on: 
Thursday, September 14, 2023
MAKE, ACT, AS, UPON, FOR, TAX, OF, NO, PAST, ITS, TIME, EACH, DATE, FINANCIAL, FUTURE, AND, IT, III, NORTH, BY, NOT, UPDATE, ALL, THIS, AMERICA, SET, USE, FCA, EUROPEAN UNION, AWARE, EXPRESS, IS, ANY, FAIR, Medical device, Audit, EU

T: +44 (0)20 3709 5700 / E: [email protected]

Key Points: 
  • T: +44 (0)20 3709 5700 / E: [email protected]
    T: +1 646 677 1811 / E: [email protected]
    THIS DOCUMENT HAS BEEN ISSUED BY DR. JONATHAN MILNER ("DR. MILNER").
  • THE VIEWS EXPRESSED HEREIN REPRESENT THE OPINIONS OF DR. MILNER AS OF THE DATE HEREOF.
  • DR. MILNER IS NOT RESPONSIBLE TO ANY PERSON FOR PROVIDING ADVICE IN RELATION TO THE SUBJECT MATTER OF THIS DOCUMENT.
  • DR. MILNER HAS NOT SOUGHT OR OBTAINED CONSENT FROM ANY THIRD PARTY TO USE ANY STATEMENTS OR INFORMATION CONTAINED HEREIN.

Dr. Jonathan Milner Announces Suspension of Proxy Solicitation

Retrieved on: 
Monday, June 26, 2023
MAKE, ACT, AS, UPON, FOR, TAX, OF, NO, PAST, ITS, TIME, EACH, CARD, DATE, FINANCIAL, FUTURE, AND, IT, III, NORTH, BY, NOT, UPDATE, ALL, THIS, AMERICA, SET, USE, FCA, EUROPEAN UNION, AWARE, EXPRESS, IS, ANY, FAIR, Medical device, Audit, EU

THIS DOCUMENT HAS BEEN ISSUED BY DR. JONATHAN MILNER ("DR. MILNER").

Key Points: 
  • THIS DOCUMENT HAS BEEN ISSUED BY DR. JONATHAN MILNER ("DR. MILNER").
  • DR. MILNER STRONGLY ADVISES ALL SHAREHOLDERS OF THE COMPANY TO READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS AS THEY BECOME AVAILABLE BECAUSE THEY CONTAIN IMPORTANT INFORMATION.
  • DR. MILNER HAS INVESTMENTS IN THE COMPANY WHICH ARE DISCLOSED IN THE PROXY STATEMENT AND OTHER PROXY MATERIALS, AND CONSEQUENTLY HAS A FINANCIAL INTEREST IN THE PROFITABILITY OF HIS POSITIONS IN THE COMPANY.
  • DR. MILNER HAS NOT SOUGHT OR OBTAINED CONSENT FROM ANY THIRD PARTY TO USE ANY STATEMENTS OR INFORMATION CONTAINED HEREIN.

Jonathan Milner calls Extraordinary General Meeting to restore focus to Abcam on governance, execution, and cost control

Retrieved on: 
Tuesday, May 30, 2023
MAKE, ACT, AS, UPON, FOR, TAX, OF, NO, PAST, ITS, TIME, EACH, DATE, FINANCIAL, FUTURE, AND, IT, III, BY, NOT, UPDATE, ALL, THIS, SET, USE, FCA, EUROPEAN UNION, AWARE, EXPRESS, IS, ANY, FAIR, Medical device, Audit, EU

SUBJECT TO THE FOREGOING, AND AS SET FORTH BELOW, DR. MILNER INTENDS TO MAKE AVAILABLE AT AN APPROPRIATE TIME ADDITIONAL INFORMATION ABOUT THE EXTRAORDINARY GENERAL MEETING INCLUDING HOW TO VOTE AT SUCH MEETING.

Key Points: 
  • SUBJECT TO THE FOREGOING, AND AS SET FORTH BELOW, DR. MILNER INTENDS TO MAKE AVAILABLE AT AN APPROPRIATE TIME ADDITIONAL INFORMATION ABOUT THE EXTRAORDINARY GENERAL MEETING INCLUDING HOW TO VOTE AT SUCH MEETING.
  • DR. MILNER HAS INVESTMENTS IN ABCAM PLC (THE “COMPANY”), AND CONSEQUENTLY HAS A FINANCIAL INTEREST IN THE PROFITABILITY OF HIS POSITIONS IN THE COMPANY.
  • DR. MILNER IS NOT RESPONSIBLE TO ANY PERSON FOR PROVIDING ADVICE IN RELATION TO THE SUBJECT MATTER OF THIS DOCUMENT.
  • DR. MILNER HAS NOT SOUGHT OR OBTAINED CONSENT FROM ANY THIRD PARTY TO USE ANY STATEMENTS OR INFORMATION CONTAINED HEREIN.